Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration .
Wave Life Sciences Announces Upcoming Presentations At MDA Conference That Highlight Best-In-Class Potential For WVE-N531 In Duchenne Muscular Dystrop menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans
CAMBRIDGE, Mass., Jan. 03, 2024 Wave Life Sciences Ltd. , a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today.